Oncology Ventures: Announces Oversubscribed $30M Fund I + Investment in mPATH
Investing in healthcare data startups that enhance cancer care and research.
Oncology Ventures In the News
Thank you to TechCrunch (link here) and Reuters (here) for covering Oncology Ventures' oversubscribed $30M Fund 1!
Appreciate the support from all of our Limited Partners (City of Hope, Cardinal Health, Moffitt Cancer Center, Atlantic Health System, New York Cancer & Blood Specialists, Astera Cancer Care, Debiopharm, Ohio State University Physicians, The Center for Cancer and Blood Disorders, Amkan Ventures and more)...
to help improve cancer care and research through our incredible portfolio companies: OncoveryCare, Gabbi, Health Universe, Inc, Reimagine Care, Concr, IgniteData and mPATH Health.
Investing in mPATH to Improve Early Detection for Lung and Colon Cancer
Lung and colon cancer are the top two drivers of cancer death in the U.S.
Despite actionable, clinically validated screening opportunities, both cancers have incredibly low screening adherence: 6% for lung and 70% for colon cancer.
This leaves 10M+ and 35M+ eligible patients unscreened for lung and colon cancer, respectively, each year.
Every one month delay in cancer treatment results in a 10% increase in mortality. And, it costs twice as much to treat metastatic cancer vs. early stage, localized cancer.
Barriers to screening for these cancer types include low awareness among eligible patients, lack of provider recommendations, cost concerns and fear of potential results.
There is also some fault on the institutional side - screening sometimes doesn’t happen because of difficult insurance requirements, where providers need to discuss the risks and benefits of certain screenings for a patient and document it before insurance covers it.
Enter mPATH: a data-driven start-up that improves early detection for lung and colon cancer by identifying, educating and empowering patients to receive timely access to relevant screening. The end-to-end platform closes the loop to help individuals schedule and complete the relevant test.
mPATH ensures patients are informed and have real-time access at no out-of-pocket cost to schedule, for example, a low-dose CT scan for lung cancer, or a colonoscopy or at-home stool test for colon cancer.
mPATH has proven it can find unseen patients (found 3x more patients due for lung cancer screening compared to EHR data and 80% of colorectal cancer screenings through their platform were individuals who had never been screened before), effectively educate patients (90% of people who validated their birthday complete their risk assessment) and empower patients to receive screening (doubled colorectal cancer screening in a randomized clinical trial).
mPATH has helped over 72,000 individuals get proper screening through its partnerships with leading institutions, including Atrium Health Wake Forest Baptist, UNC Health and Chess Health Solutions.
Oncology Ventures is proud to lead their Seed Financing and support Dr. Dave Miller, Dr. Ajay Dharod and team as they bring much needed preventive care to populations who need support.
If you are a healthcare system, FQHC, at-risk primary care group or other looking to improve lung and colon cancer screening for your population, please reach out to us.
Comedy!
When do they decide to put the “Original” sign on restaurants? I love when two Ray’s Pizza’s, who are on the same NYC block, both have an Original sign on their door. It’s like a bunch of toddlers fighting "Ugh Dad, tell them we were here first!"
Do they think it helps with business? Hey our competitors may have better crust, sauce and overall taste, but… we were here first. So, that should matter. That’s like claiming you’re the best because you were the first one to show up at a party. It doesn’t make you popular, it just means you had nothing better to do.
These pizza shops even try to one-up each other from there. They’ll add in a Famous before the Original sign. Why would I go to get a slice at boring, copycat Ray’s Pizza, when I could walk one more block to the Famous Original Ray’s?
Reminds me of those people you see on LinkedIn who have President & CEO in their title. Why the extra claim? We get it. You’re in charge. It’s like wearing a belt and suspenders. Pick a lane.
Are they worried that if they drop one of those titles, someone would come into a meeting and say “Ehh you’re only the CEO… who is really making the decisions here? If you were also the President, then we could have a real conversation.”
Thanks for reading this post written by the Founder & Managing Partner of the Original cancer venture capital fund.
Ask
If you ever see “cancer” and “data” together in a start-up deck, article or event, please continue to send our way.
Congratulations! I'm excited for the improvements this will bring to the cancer community.